abstract
Aim: This study aimed to derive meaningful parameters for immune
monitoring during cancer vaccine development by analysis of the
literature.
Methods: This retrospective study was based on analysis of clinical trials registered at ClinicalTrials.gov and published data available on PubMed.
Results:
The most common sample evaluated in immune monitoring was peripheral
blood. All trials employed ELISA for detecting a humoral immune
response; however, cellular immune assays were not used across trials.
Most cellular immune assays failed to correlate with clinical outcome,
although results of other methods did. Conclusion:
Standardization of the cellular immune assays across trials is important
for predicting the effects of therapeutic cancer vaccines when
considering the reliability and characteristics of the methods.
Currently, assays mostly target detection of T-cell function, such as
proliferation and cytokine release; however, T-cell phenotype analysis
in peripheral blood and/or tumor sites may also be considered in the
future.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.